Tilman Todenhöfer

4.9k total citations · 1 hit paper
169 papers, 2.7k citations indexed

About

Tilman Todenhöfer is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Tilman Todenhöfer has authored 169 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Surgery, 67 papers in Pulmonary and Respiratory Medicine and 61 papers in Oncology. Recurrent topics in Tilman Todenhöfer's work include Bladder and Urothelial Cancer Treatments (87 papers), Urinary and Genital Oncology Studies (57 papers) and Prostate Cancer Treatment and Research (41 papers). Tilman Todenhöfer is often cited by papers focused on Bladder and Urothelial Cancer Treatments (87 papers), Urinary and Genital Oncology Studies (57 papers) and Prostate Cancer Treatment and Research (41 papers). Tilman Todenhöfer collaborates with scholars based in Germany, Canada and United States. Tilman Todenhöfer's co-authors include Arnulf Stenzl, Christian Schwentner, Georgios Gakis, Peter C. Black, Stefan Aufderklamm, Jörg Hennenlotter, Steffen Rausch, Moritz Maas, Kim N. and Jens Bedke and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Tilman Todenhöfer

161 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Urine biomarkers in bladder cancer — current status and future perspectives

2023 66 citations Moritz Maas, Tilman Todenhöfer et al. profile →

Peers

Countries citing papers authored by Tilman Todenhöfer

Since Specialization

Citations

This map shows the geographic impact of Tilman Todenhöfer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tilman Todenhöfer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tilman Todenhöfer more than expected).

Fields of papers citing papers by Tilman Todenhöfer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tilman Todenhöfer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tilman Todenhöfer. The network helps show where Tilman Todenhöfer may publish in the future.

Co-authorship network of co-authors of Tilman Todenhöfer

This figure shows the co-authorship network connecting the top 25 collaborators of Tilman Todenhöfer. A scholar is included among the top collaborators of Tilman Todenhöfer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tilman Todenhöfer. Tilman Todenhöfer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC 2025 ·Oncology and Therapy ·Bernadett Szabados, Félix Guerrero‐Ramos, Enrique Grande, Petros Grivas, Viktor Grünwald, (unknown), Syed A. Hussain, Girish S. Kulkarni, Anne Wilson, Neal D. Shore, Srikala S. Sridhar, (unknown), (unknown), (unknown), (unknown), Rosemary E. Teresi, Tilman Todenhöfer	0
2	Interleukin-1β/Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) Axis in Invasive Bladder Cancer—An Exploratory Analysis of Clinical and Tumor Biological Significance 2024 ·International Journal of Molecular Sciences ·(unknown), (unknown), Jörg Hennenlotter, Tilman Todenhöfer, (unknown), (unknown), Igor Tsaur, Arnulf Stenzl, Steffen Rausch	2
3	Abstract A007: Circulating tumor DNA and tissue staining analyses reveal heterogeneous ERBB2/HER2 status in urothelial cancer 2024 ·Clinical Cancer Research ·Gillian Vandekerkhove, Andrew J. Murtha, David C. Müller, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Cecily Q. Bernales, (unknown), Gang Wang, Tilman Todenhöfer, Piet Ost, Peter C. Black, Kim N., Bernhard J. Eigl, Alexander W. Wyatt	0
4	Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1 2023 ·Urologic Oncology Seminars and Original Investigations ·Patrick J. Hensley, Roland Seiler, Harry W. Herr, Kent W. Mouw, Gopa Iyer, Lars Dyrskjøt, Roman Nawroth, Peter J. Goebell, Bernd J. Schmitz‐Dräger, Tilman Todenhöfer, Peter C. Black, Ashish M. Kamat, Stephen B. Williams	1
5	Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases 2023 ·International Journal of Molecular Sciences ·Moritz Maas, (unknown), Jörg Hennenlotter, Marcus Scharpf, Falko Fend, Simon Walz, Viktoria Stühler, Tilman Todenhöfer, Arnulf Stenzl, Jens Bedke, Steffen Rausch	2
6	Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study. 2023 ·Journal of Clinical Oncology ·Andrea Necchi, Tilman Todenhöfer, Jean‐Laurent Deville, (unknown), (unknown), (unknown), Mikael Saulay, Marc Engelhardt, Maria De Santis	4
7	CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). 2023 ·Journal of Clinical Oncology ·Matthew R. Smith, Nobuaki Matsubara, Rana R. McKay, Josep M. Piulats, Tilman Todenhöfer, Tian Zhang, Nicolas Fasnacht, (unknown), (unknown), (unknown), Andrew Lithio, (unknown), Neeraj Agarwal	3
8	Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2023 ·Journal of Clinical Oncology ·Daniel P. Petrylak, Raffaele Ratta, Nobuaki Matsubara, Ernesto Korbenfeld, Rustem Gafanov, Loı̈c Mourey, Tilman Todenhöfer, Howard Gurney, Gero Kramer, Andries M. Bergman, Paweł Zalewski, Maria De Santis, Andrew J. Armstrong, Winald R. Gerritsen, Russell K. Pachynski, (unknown), Sameer R. Ghate, (unknown), Charles Schloss, Karim Fizazi	1
9	Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems 2022 ·International Journal of Molecular Sciences ·(unknown), Bastian Amend, Tilman Todenhöfer, (unknown), Wilhelm K. Aicher, Falko Fend, Arnulf Stenzl, (unknown)	12
10	Comparison of the metabolome in urine prior and eight weeks after radical prostatectomy uncovers pathologic and molecular features of prostate cancer 2021 ·Journal of Pharmaceutical and Biomedical Analysis ·Simon Walz, Qingqing Wang, Xinjie Zhao, Miriam Hoene, Hans‐Ulrich Häring, Jörg Hennenlotter, Moritz Maas, Andreas Peter, Tilman Todenhöfer, Arnulf Stenzl, Xinyu Liu, Rainer Lehmann, Guowang Xu	3
11	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer 2021 ·Nature Communications ·Gillian Vandekerkhove, Jean‐Michel Lavoie, Matti Annala, Andrew J. Murtha, Nora Sundahl, Simon Walz, Takeshi Sano, Sinja Taavitsainen, Elie Ritch, Ladan Fazli, Antonio Hurtado‐Coll, Gang Wang, Matti Nykter, Peter C. Black, Tilman Todenhöfer, Piet Ost, Ewan A. Gibb, Kim N., Bernhard J. Eigl, Alexander W. Wyatt	109
12	A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine 2020 ·Cell Death Discovery ·Thomas Mandel Clausen, (unknown), (unknown), (unknown), Antonio Hurtado‐Coll, Tobias Gustavsson, Mette Ø. Agerbæk, Francesco Gatto, Tilman Todenhöfer, Umberto Basso, Margaret A. Knowles, Marta Sänchez‐Carbayo, Ali Salanti, Peter C. Black, Mads Daugaard	7
13	Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer 2019 ·American Journal Of Pathology ·Renate Pichler, Andrea Katharina Lindner, Éva Compérat, Peter Obrist, Georg Schäfer, Tilman Todenhöfer, Wolfgang Horninger, Zoran Čulig, Gerold Untergasser	6
14	Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review 2019 ·The World Journal of Men s Health ·Simon Walz, Moritz Maas, Arnulf Stenzl, Tilman Todenhöfer	6
15	Perioperative morbidity, bowel function and oncologic outcome after radical cystectomy and ileal orthotopic neobladder reconstruction: Studer-pouch versus I-pouch 2017 ·European Journal of Surgical Oncology ·Johannes Mischinger, (unknown), Steffen Rausch, Tilman Todenhöfer, Eva Neumann, Stefan Aufderklamm, Arnulf Stenzl, Georgios Gakis	6
16	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer 2017 ·Clinical Cancer Research ·Gillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, Werner J. Struss, Amanda Wong, Kevin Beja, Elie Ritch, Sonal Brahmbhatt, Stanislav Volik, Jörg Hennenlotter, Matti Nykter, Kim N., Scott North, Arnulf Stenzl, Colin C. Collins, Bernhard J. Eigl, Peter C. Black, Alexander W. Wyatt	122
17	Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer 2015 ·The Journal of Urology ·Tetsutaro Hayashi, Roland Seiler, Htoo Zarni Oo, Wolfgang Jäger, Igor Moskalev, Shannon Awrey, Takashi Dejima, Tilman Todenhöfer, Na Li, Ladan Fazli, Akio Matsubara, Peter C. Black	70
18	Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy 2015 ·World Journal of Urology ·Georgios Gakis, (unknown), Steffen Rausch, Johannes Mischinger, Tilman Todenhöfer, Christian Schwentner, (unknown), (unknown), M. Renninger, Arnulf Stenzl	27
19	Y Pouch Neobladder—A Simplified Method of Intracorporeal Neobladder After Robotic Cystectomy 2014 ·Journal of Endourology ·(unknown), Tilman Todenhöfer, Johannes Mischinger, (unknown), Omar Fahmy, (unknown), Steffen Rausch, Simone Bier, Stefan Aufderklamm, Evangelos Liatsikos, Arnulf Stenzl, Georgios Gakis, Christian Schwentner	14
20	Bilateral Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection in Nonseminomatous Germ Cell Tumors–a Comparison to Template Dissection 2013 ·Journal of Endourology ·Stefan Aufderklamm, Tilman Todenhöfer, Jörg Hennenlotter, Georgios Gakis, Johannes Mischinger, (unknown), (unknown), Arnulf Stenzl, Christian Schwentner	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact